Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | F3 | P13726 | 2/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.50 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.50 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20134914 | 0.81 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2AHTTHIF1A | |
| SCHEMBL9449106 | 0.81 | ABCG2 (0.53) | ALDH1A1MEN1KMT2AHTTHIF1A | |
| SCHEMBL9448934 | 0.81 | KMT2A (0.56) | ALDH1A1MEN1KMT2AHTTHIF1A | |
| SCHEMBL9448898 | 0.80 | ABCG2 (0.59) | ALDH1A1MEN1KMT2AHTTCES2 | |
| SCHEMBL9448941 | 0.79 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AHTTHIF1A | |
| SCHEMBL9449020 | 0.79 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2AHTTHIF1A | |
| SCHEMBL7000261 | 0.78 | F3 (0.75) | ALDH1A1MEN1KMT2AF3CES2 | |
| SCHEMBL7000262 | 0.78 | F3 (0.75) | ALDH1A1MEN1KMT2AF3CES2 | |
| SCHEMBL4607255 | 0.77 | KMT2A (0.56) | ALDH1A1MEN1KMT2AHTTHIF1A | |
| SCHEMBL28111426 | 0.76 | CES2 (0.61) | ALDH1A1MEN1KMT2AF3CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113248458-B | Preparation method of alpha-carbonyl amide compound | 陕西省煤田地质集团有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-113248458-A | Preparation method of alpha-carbonyl amide compound | 陕西省煤田地质集团有限公司 | 2021-08-13 | — | — | CN | disclosed |
| US-9751825-B2 | TAK1 kinase inhibitors, compositions, and used related thereto | EMORY UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| US-20140249199-A1 | TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO | HEALTH RESEARCH, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| EP-0466730-B1 | GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS | THE UPJOHN COMPANY (US) | 1993-07-21 | — | — | EP | disclosed |
| US-5220021-A | Geminal bisphosphonic acids and derivatives as anti-arthritic agents | THE UPJOHN COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
| WO-1990012017-A1 | GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS | THE UPJOHN COMPANY (US) | 1990-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249199-A1 | TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO | TAB1, MAP3K1, MAP3K6 | ALDH1A1 3574/4885MEN1 1525/4885KMT2A 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.